TRAVAGLINI, DANIELA
 Distribuzione geografica
Continente #
NA - Nord America 586
EU - Europa 530
AS - Asia 302
Continente sconosciuto - Info sul continente non disponibili 3
Totale 1.421
Nazione #
US - Stati Uniti d'America 586
CN - Cina 178
UA - Ucraina 107
SE - Svezia 90
GB - Regno Unito 86
TR - Turchia 84
IT - Italia 61
FR - Francia 52
IE - Irlanda 51
DE - Germania 46
IN - India 31
FI - Finlandia 25
BE - Belgio 8
IR - Iran 4
EU - Europa 3
GR - Grecia 2
KR - Corea 2
DK - Danimarca 1
IL - Israele 1
PH - Filippine 1
RU - Federazione Russa 1
TW - Taiwan 1
Totale 1.421
Città #
Chandler 152
Jacksonville 144
Southend 80
Princeton 52
Dublin 51
Nanjing 50
Beijing 41
Izmir 39
Dearborn 26
Cambridge 24
Nanchang 18
Wilmington 18
Altamura 16
Ann Arbor 12
Grevenbroich 12
Chieti 10
Shenyang 9
Washington 9
Brussels 8
Norwalk 8
Torino 8
Kunming 7
Hangzhou 6
Tianjin 6
Changchun 5
Changsha 5
Guangzhou 5
Hebei 5
Jiaxing 4
Jinan 4
Lanzhou 4
Monmouth Junction 4
Ardabil 3
Augusta 3
San Mateo 3
San Vito Chietino 3
Boardman 2
Campobasso 2
Leawood 2
Mumbai 2
Ningbo 2
Redmond 2
Taizhou 2
Woodbridge 2
Zhengzhou 2
Andover 1
Bangalore 1
Capurso 1
Centrale 1
Chengdu 1
Hanover 1
Helsinki 1
London 1
Manila 1
Moscow 1
Mountain View 1
Orange 1
Parrano 1
Phoenix 1
Quanzhou 1
Rome 1
San Jose 1
San Salvo 1
Taipei 1
Walnut 1
Totale 892
Nome #
Cleavage of cystatin C is not associated with multiple sclerosis 92
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 82
Metabolomics analysis of cerebrospinal fluid reveals a distintive biochemical alteration associated with multiple sclerosis. 74
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 73
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 67
Increasing age at disability milestones among MS patients in the MSBase Registry 65
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 64
Development of methods for lipid extraction from CSF and application of mass spectometry techniques for the characterization of the lipid profile and neurosteroids levels in MS patients 61
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 58
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 57
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 56
JCV-Ab serostatus in MS patients treated with Natalizumab 56
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 56
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 56
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 56
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 54
Natalizumab-associated PML-IRIS: the Chieti experience. 54
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 54
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 52
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 51
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 49
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 48
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis 43
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 38
New daily persistent headache after SARS-CoV-2 infection: a report of two cases 24
Totale 1.440
Categoria #
all - tutte 3.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.561


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019147 0 0 0 2 55 1 27 1 0 0 1 60
2019/2020324 96 24 2 2 23 26 40 32 10 29 38 2
2020/2021126 24 0 25 0 1 26 0 0 20 8 20 2
2021/2022119 0 4 6 29 5 2 10 8 10 3 13 29
2022/2023394 26 62 25 29 47 72 25 30 58 5 7 8
2023/202439 12 10 17 0 0 0 0 0 0 0 0 0
Totale 1.440